June 17, 2022 : Track 1
Scientific Session 1 : Asian Clinical Highlights
| Time & Date | 09:00-10:30 Friday, June 17, 2022 |
|---|---|
| Chairperson | Hyo Jong Kim (Kyung Hee University, Korea) |
| Tadakazu Hisamatsu (Kyorin University School of Medicine, Japan) | |
| Speaker | SS1-1Is histological healing an ultimate treatment target? Taku Kobayashi (Kitasato University Kitasato Institute Hospital, Japan) |
| SS1-2Sharing Experience of Building a high quality IBD-MDT team Yao He (Hospital of Sun Yat-sen University, China) |
|
| SS1-3Inflammatory bowel disease during pregnancy and their offspring’s intestinal health Eun Soo Kim (Kyungpook National University, Korea) |
|
| SS1-4Impacts of COVID-19 Pandemic on Patient Perceptions and Inflammatory Bowel Disease Care: A Multicenter Study of TSIBD Chen-Shuan Chung (Far Eastern Memorial Hospital, Taiwan) |
Distinguished Session 2 : Recent advances in stem cell and cancer biology in IBD
| Time & Date | 10:45-11:45 Friday, June 17, 2022 |
|---|---|
| Chairperson | Toshifumi Hibi (Kitasato University Kitasato Institute Hospital, Japan) |
| Keynote Speaker | D2-1Understanding of gastrointestinal diseases using organoid technology Toshiro Sato (Keio University School of Medicine, Japan) |
Symposium 1 : Emerging concepts in pathophysiology of IBD
| Time & Date | 13:00-14:15 Friday, June 17, 2022 |
|---|---|
| Chairperson | Young Sook Park (EULJI UNIVERSITY MEDICAL CENTER, Korea) |
| Katsuyoshi Matsuoka (Toho University Sakura Medical Center, Japan) | |
| Keynote Speaker | SY1-KPlant derived medicine targeting the mucosal healing of ulcerative colitis Takanori Kanai (Keio University, School of Medicine, Japan) |
| Speaker | SY1-1Microbiota-derived lysophosphatidylserines elicit pathological Th1 response in Crohn’s disease Hisako Kayama (Osaka University Imunology Frontier Reserarch Center, Japan) |
| SY1-2Macrophages in Intestinal Inflammation and Resolution Seung Hyeok Seok (Seoul National University, Korea) |
|
| SY1-3Emerging concepts in pathophysiology of IBD Zhanju Liu (The Shanghai Tenth People's Hospital, Tongji University, China) |
Scientific Session 4 : IBD-associated cancer: Diagnosis and management
| Time & Date | 14:30-15:45 Friday, June 17, 2022 |
|---|---|
| Chairperson | Deng-Chyang Wu (Kaohsiung Medical University Chung-Ho Memorial Hospital, Taiwan) |
| Haruhiko Ogata (Keio University School of Medicine, Japan) | |
| Speaker | SS4-1Advance in endoscopic management for colorectal neoplasms occurring in UC Takayuki Matsumoto (Iwate Medical University, Japan) |
| SS4-2Advances in surgical treatment for ulcerative colitis-associated neoplasia Soichiro Ishihara (The University of Tokyo Hospital, Japan) |
|
| SS4-3Advance in surveillance colonoscopy for ulcerative colitis-associated neoplasia Dong-Hoon Yang (Asan Medical Center, University of Ulsan College of Medicine, Korea) |
Distinguished Session 3 : Biologics and cytokine networks in IBD
| Time & Date | 16:00-17:00 Friday, June 17, 2022 |
|---|---|
| Chairperson | Atsushi Mizoguchi (Kurume University School of Medicine, Japan) |
| Keynote Speaker | D3-1Biologics and cytokine networks in IBD Markus Neurath (Friedrich-Alexander-Universität Erlangen-Nürnberg, German) |
June 17, 2022 : Track 2
Distinguished Session 1 : Patient cohort study in IBD
| Time & Date | 09:00-10:30 Friday, June 17, 2022 |
|---|---|
| Chairperson | Yoon Tae Jeen (Korea University Anam Hospital, Korea) |
| Katsuyoshi Matsuoka (Toho University Sakura Medical Center, Japan) | |
| Keynote Speaker | D1-1IBD Qorus: A United States IBD Cohort to Improve Quality of Care Corey Siegel (Dartmouth-Hitchcock Medical Center, USA) |
| D1-2INFLUENCE OF PROTON PUMP INHIBITOR USE ON CLINICAL OUTCOMES OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE Atsushi Sakuraba (University of Chicago, USA) |
Scientific Session 2 : Advances in IBD genetics
| Time & Date | 10:45-11:45 Friday, June 17, 2022 |
|---|---|
| Chairperson | Byong Duk Ye (Asan Medical Center, University of Ulsan College of Medicine, Korea) |
| Hiroshi Nakase (Sapporo Medical University School of Medicine, Japan) | |
| Speaker | SS2-1Mosaic chromosomal alterations in Japanese patients with inflammatory bowel diseases Yoichi Kakuta (Tohoku University, Japan) |
| SS2-2Clinical genomics in Inflammatory bowel disease: is it ready for use in clinical decision-making? Ho-Su Lee (Asan Medical Center, University of Ulsan College of Medicine, Korea) |
|
| SS2-3Advances in IBD genetics Zhanju Liu (The Shanghai Tenth People's Hospital of Tongji University, China) |
Scientific Session 3 : Advances in surgical management of IBD
| Time & Date | 13:00-14:15 Friday, June 17, 2022 |
|---|---|
| Chairperson | Tzu-Chi Hsu (Mackay Memorial Hospital, Taiwan) |
| Hiroki Ikeuchi (Hyogo College of Medicine, Japan) | |
| Speaker | SS3-1The Prospects for the Future of Laparoscopic Surgery for Ulcerative Colitis Koji Okabayashi (Keio University School of Medicine, Japan) |
| SS3-2Withdraw | |
| SS3-3Kono-S anastomosis for patients with Crohn’s disease Hiroki Ohge (Hiroshima University Hospital, Japan) |
Scientific Session 5 : Diagnostic and Therapeutic Challenges in Monogenic IBD
| Time & Date | 14:30-15:45 Friday, June 17, 2022 |
|---|---|
| Chairperson | Way-Seah Lee (University Malaya, Malaysia) |
| Takashi Ishige (Gunma University, Japan) | |
| Keynote Speaker | SS5-KNext Generation Diagnosis of VEO IBD Daniel Kotlarz (Ludwig-Maximilians-Universität München, Germany) |
| Speaker | SS5-1Whole-Exome Sequencing for Pediatric-onset Inflammatory Bowel Disease: A Japanese Experience. Ichiro Takeuchi (National Center for Child Health and Development, Japan) |
| SS5-2Digital Approach in Monogenic IBD Seak Hee Oh (Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Korea) |
Workshop 1 : Management of IBD under COVID-19 pandemic (or post-corona, before/after)
| Time & Date | 16:00-17:30 Friday, June 17, 2022 |
|---|---|
| Chairperson | Tadakazu Hisamatsu (Kyorin University School of Medicine, Japan) |
| Keynote Speaker | WS1-KManagement of IBD under COVID-19 pandemic Silvio Danese (IRCCS San Raffaele Hospital - Vita-Salute San Raffaele University, Italy) |
| Discussant | Raja Affendi Raja Ali (The National University of Malaysia, Malaysia) |
| Speaker | WS1-1IBD management in the COVID-19 pandemic, as revealed by data from J-COSMOS and J-DESIRE Nakase Hiroshi (Sapporo Medical University School of Medicine, Japan) |
| WS1-2Management of IBD during the COVID
19 pandemic: The India perspective Rupa Banerjee (Asian Institute of Gastroenterology, India) |
|
| WS1-3Withdraw | |
| WS1-4IBD and COVID-19 pandemic: Current status and future perspectives in Korea Sang Hyoung Park (Asan Medical Center, University of Ulsan College of Medicine, Korea) |
|
| WS1-5The Influence of Corticosteroids, Immunosuppressants and Biologics on outcome of Patients With Inflammatory Bowel Diseases based on data from SECURE-IBD registry Hong Yang (Peking Union Medical College Hospital, China) |
June 17, 2022 Track 3
Oral Session 1
| Time & Date | 09:00-10:00 June 17 (JST) |
|---|---|
| Chairperson | Seung-Jae Myung (Asan Medical Center, University of Ulsan College of Medicine, Korea) |
| Fumihito Hirai (Fukuoka University Faculty of Medicine, Japan) | |
| Speakers | O1-1Aryl hydrocarbon receptor signals in epithelial cells govern the recruitment and location of Helios+ Tregs in the gut. Yusuke Yoshimatsu |
| O1-2Asymmetric vagal regulation in the maintenance of intestinal regulatory T-helper cells. Yohei Mikami |
|
| O1-3IL-17–dependent fibroblastic reticular cell training boosts tissue protective mucosal immunity through IL-10–producing B cells Dongwen Wu |
|
| O1-4Gut microbiome associates with the occurrence of immune-related adverse event and immune-related colitis Xinyu Liu |
|
| O1-5Intestinal Ultrasound Predicts Disease Behavior Progression in Patients with Crohn’s Disease: A Single-center, Retrospective Study Jinshen He |
|
| O1-6Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker For Transmural Inflammation in Crohn's Disease Kento Takenaka |
Oral Session 2
| Time & Date | 10:45-11:45 June 17 (JST) |
|---|---|
| Chairperson | Dong Il Park (Kangbuk Samsung Hospital, Sungkyunkwan Univiersity School of Medicine, Korea) |
| Kiichiro Tsuchiya (University of Tsukuba, Japan) | |
| Speakers | O2-1Neutrophil restrains intestinal inflammation through regulation of microbial metabolite dimethyl fumarate to orchestrate IEL homeostasis Huimin Chen |
| O2-2UHRF1-mediated NPY1R gene methylation protects intestinal epithelial cells through activation of CREB signaling Yanan Han |
|
| O2-3The Comprehensive proteomic investigation of Cronkhite-Canada syndrome: possible evidence for pathogenesis Runfeng Zhang |
|
| O2-4Efficacy and Safety of Combination Induction Therapy with Guselkumab and Golimumab in Participants with Moderately-to-Severely Active Ulcerative Colitis Cao Qian |
|
| O2-5withdraw |
|
| O2-6Compositional differences of gut microbiome using taxonomic profiling in patients with ulcerative colitis after treatment with vedolizumab Aran Yoon |
Oral Session 3
| Time & Date | 13:00-14:00 June 17 (JST) |
|---|---|
| Chairperson | David ONG (National Univertisty Hospital, Singapore) |
| Akihiro Yamada (Sakura medical Center, Toho University, Japan) | |
| Speakers | O3-1Long-Term Outcomes After Histologic-Endoscopic Mucosal Healing (HEMH): Results from the UNIFI Study in Ulcerative Colitis (UC) Rupert Leong |
| O3-2Fecal leukocyte esterase strip test results correlated with fecal calprotectin level for inflammatory bowel disease (IBD) patients Meng-Tzu Weng |
|
| O3-3A universal gut microbiome signature for diagnosis of Crohn’s disease Jingwan Zhang |
|
| O3-4Efficacy of treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's disease from the STARTDUST trial Hiroshi Nakase |
|
| O3-5Combination of fecal microbiota transplantation and anti-inflammatory diet induces clinical and deep remission in patients with mild-moderate ulcerative colitis Saurabh Kedia |
|
| O3-6The role of serum Leucine-rich alpha-2 glycoprotein in disease monitoring for ulcerative colitis Yuki Aoyama |
Oral Session 4
| Time & Date | 14:30-15:30 June 17 (JST) |
|---|---|
| Chairperson | Leung Wai-Keung (Queen Mary Hospital, University of Hong Kong, Hong Kong) |
| Toshimitsu Fujii (Tokyo Medical and Dental University, Japan) | |
| Speakers | O4-1Correlation of histological mucosal healing with long-term clinical and patient-reported outcomes in moderate to severe ulcerative colitis treated with upadacitinib Yuri Sanchez Gonzalez |
| O4-2MR Enterography Radiomic Approach Helps for Characterization of Intestinal Fibrosis in Crohn's Disease Mengchen Zhang |
|
| O4-3Schlafen11 is a potential biomarker for mucosal residual inflammation and a target for JAK inhibitor therapy. Yasuhisa Murai |
|
| O4-4Optimal timing of assessing improvement in bowel wall thickness by transperineal ultrasonography may differ among induction therapies in ulcerative colitis Shintaro Sagami |
|
| O4-5Venlafaxine as an Adjuvant Therapy for IBD Patients with Anxious and Depressive Symptoms: A Randomized Controlled Trial Chang Liang |
|
| O4-6Risankizumab therapy results in sustained improvements in endoscopic outcomes in patients with moderate-to-severe Crohn’s disease: Phase 3 FORTIFY post-hoc analysis Kristina Kligys |
Oral Session 5
| Time & Date | 16:00-17:00 June 17 (JST) |
|---|---|
| Chairperson | Shintaro Akiyama (University of Tsukuba, Japan) |
| Speakers | O5-1The association between mesenteric fat hyperplasia and disease activity in Crohn′s disease He Jinshen |
| O5-2LONG-TERM CLINICAL EFFECTIVENESS OF USTEKINUMAB IN JAPANESE PATIENTS WITH CROHN’S DISEASE: A RETROSPECTIVE COHORT STUDY Takahiro Ito |
|
| O5-3Linked color imaging diagnoses mucosal inflammation and predict relapse in UC patients with MES 0. Kohei Asaeda |
|
| O5-4Distinct alterations of fecal microbiotas refer to the efficacy of adalimumab in Crohn’s disease leilei fang |
|
| O5-5Efficacy and safety of long-term treatment with filgotinib 200 mg among patients with ulcerative colitis: an interim analysis of SELECTIONLTE Katsuyoshi Matsuoka |
|
| O5-6The IBD-disk accurately predicts the daily life burden and correlates with disease activity in patients with Inflammatory Bowel Disease Arshdeep Singh |